AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 4 - (NewsRx.com & NewsRx.net) -- A novel educational intervention does not improve adherence to HIV treatment in minority patients.
According to published research from Texas, "A 24-week open-label clinical trial was conducted in 195 HIV-infected adults commonly underrepresented in research (35% female, 71% African American, 21% Hispanic, and 20% injection drug users [IDUs]) to evaluate the effect of an HIV educational program on efficacy and adherence with a simple, compact, twice-daily triple nucleoside regimen containing a lamivudine (150 mg)/zidovudine (300 mg) combination (COM) tablet plus abacavir (ABC), 300 mg."
"At baseline, the patients' median plasma HIV-1 RNA level was 4.18 log[subscript]10 copies/mL and the median CD4+ cell count was 379 celIs/mm[superscript]3," noted M.K. Rawlings and coauthors working at the Southeast Dallas Health Center. "Patients were randomized 1:1 to four modules of the Tools for Health and Empowerment HIV education intervention plus routine counseling (EI+RC; n=96) or to routine counseling alone (RC; n=99)."
"No differences between the EI+RC and RC treatment arms were observed with respect to the proportion of patients achieving plasma HIV-1 RNA levels
The researchers concluded that, "in under-represented patients, the EI used in this study did not affect the efficacy and adherence results with ABC+COM to any greater degree than did RC."
...
Source: HighBeam Research, Educational program fails to improve adherence to HIV treatment in...